Loading
A phase 1/2 trial of VS-7375, Cetuximab, Carboplatin in pancreatic ductal adenocarcinoma and non-small-cell lung cancer, run by Verastem, Inc., now recruiting.
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors is a phase 1/2 interventional study registered as NCT07020221 by Verastem, Inc., with 295 participants planned, started 2025-06-24 and due to reach its primary completion in 2028-12. Interventions recorded: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine, Gemcitabine + Nab-paclitaxel. Conditions listed: Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult. No results are recorded here; the registry entry is the source.
Shares VS-7375, Verastem Oncology, Small-cell lung cancer, Non-small-cell lung cancer.
Shares VS-7375, Verastem Oncology, Cetuximab, Pancreatic ductal adenocarcinoma.
Shares Cetuximab, Gemcitabine, Small-cell lung cancer, Pembrolizumab.
Shares VS-7375, Verastem Oncology, Cetuximab, Colorectal cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Pembrolizumab.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Pemetrexed, Gemcitabine, Carboplatin, Small-cell lung cancer.